Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2182 - Dynamics of changes in endocrine status in adolescents with lymphoma


08 Oct 2016


Poster Display


Elena Pak


Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375


E. Pak1, O. Kit2, E. Frantsiyants3, V. Dmitrieva4, O. Kozyuk1, I. Lysenko1, L. Vladimirova5

Author affiliations

  • 1 Department Of Hematology, Rostov Research Institute of Oncology, 344037 - Rostov on Don/RU
  • 2 Surgical Department, Rostov Research Institute of Oncology, 344037 - Rostov on Don/RU
  • 3 Laboratory Of Study Of Malignant Tumor Pathogenesis, Rostov Research Institute of Oncology, Rostov on Don/RU
  • 4 Department Of Pediatric Surgery, Rostov Research Institute of Oncology, Rostov on Don/RU
  • 5 Department Of Chemotherapy, Rostov Research Institute of Oncology, 344037 - Rostov on Don/RU


Abstract 2182


The purpose of the study was to analyze the endocrine status of patients with Hodgkin lymphoma (HL) before treatment and the effect of chemotherapy on sex, pituitary and glucocorticoid hormones.


Gonadal function, its regulation by tropic pituitary hormones and levels of prolactin and cortisol were studied by radioimmunoassay in 32 HL patients aged 12-21 years receiving chemotherapy.


Before therapy females showed estradiol decreased by 10 times compared with the norm in follicular and luteal phases of the cycle, with testosterone increase by 3.7 times in phase I and by 10 times in phase II of the cycle. Follicle-stimulating hormone (FSH) was 10 times lower than the norm. Luteinizing hormone in the luteal phase was similar to the norm in all disease stages, and in the follicular phase it was decreased by 15 times in patients with stage III-IV disease, compared with the norm. Male patients, especially those with stage III-IV disease, showed low testosterone levels in the blood before treatment. Significant overproduction of estradiol was observed, especially in stages III-IV. FSH levels in stage III-IV patients were 11 times lower than the norm; cortisol content did not change in stages I-II, and in stages III-IV it was 2.5 times higher than the norm. Prolactin and progesterone levels were similar to the norm.


HL development in adolescents is accompanied by significant changes in levels of sex and pituitary hormones and cortisol depending on the disease stage. Chemotherapy provides high antitumor effect and normalizes the levels of circulating hormones that have changed before the treatment.

Clinical trial identification

Legal entity responsible for the study

Rostov Research Institute of Oncology


Ministry of Health of the Russian Federation


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings